COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
Cimbollek
Stefan
S
Quiralte
Joaquin
J
Avila
Robledo
R
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D004342:Drug Hypersensitivity; D000077613:Etoricoxib; D005260:Female; D006801:Humans; D008297:Male; D011720:Pyrazoles / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D013449:Sulfonamides; D013450:Sulfones; D000068579:Celecoxib; D000077613:Etoricoxib